Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression

Toxicology and Applied Pharmacology

Volumn 217, Issue 3, 2006, Pages 352-362

  Hreiche, Raymond ^a   Mégarbane, Bruno ^a,b   Pirnay, Stéphane ^a,c   Borron, Stephen W ^a,d   Monier, Claire ^a   Risède, Patricia ^a   Milan, Nathalie ^c   Descatoire, Véronique ^a   Pessayre, Dominique ^a   Baud, Frédéric J ^a,b  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Université René Descartes Paris 5   (France)

^d University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Buprenorphine; Cytochrome P450; Liver metabolism; Norbuprenorphine; Plethysmography; Respiratory depression

Indexed keywords

BUPRENORPHINE; CYTOCHROME P450 3A; DEXAMETHASONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; BODY PLETHYSMOGRAPHY; BREATHING RATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; LUNG MINUTE VOLUME; LUNG VENTILATION; MALE; MONOTHERAPY; NONHUMAN; PARAMETER; PROTEIN INDUCTION; RAT; RESPIRATION DEPRESSION; TIDAL VOLUME;

ANIMALIA;

EID: 33845349258     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.09.011     Document Type: Article

References (52)

1. Bailey P.L., Lu J.K., Pace N.L., Orr J.A., White J.L., Hamber E.A., Slawson M.H., Crouch D.J., and Rollins D.E. Effects of intrathecal morphine on the ventilatory response to hypoxia. N. Engl. J. Med. 343 (2000) 1228-1234
2. Bartlett D., and Tenney S.M. Control of breathing in experimental anemia. Respir. Physiol. 10 (1970) 384-395
3. Berson A., Fau D., Fornacciari R., Degove-Goddard P., Sutton A., Descatoire V., Haouzi D., Letteron P., Moreau A., Feldmann G., and Pessayre D. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J. Hepatol. 34 (2001) 261-269
4. Bonora M., Bernaudin J.F., Guernier C., and Brahimi-Horn M.C. Ventilatory responses to hypercapnia and hypoxia in conscious cystic fibrosis knockout mice Cftr-/-. Pediatr. Res. 55 (2004) 738-746
5. Borron S.W., Monier C., Risède P., and Baud F.J. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum. Exp. Toxicol. 21 (2002) 599-605
6. Campbell C., Weinger M.B., and Quinn M. Alterations in diaphragm activity during opiate-induced respiratory depression. Respir. Physiol. 100 (1995) 107-117
7. Cowan A., Doxey J., and Harry E. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 60 (1977) 547-554
8. Donoghoe M., and Hall W. Opioid Overdose: Trends, Risk Factors, Interventions, and Priorities for Action (1998), World Health Organization, Geneva
9. Dosaka-Akita K., Tortella F.C., Holaday J.W., and Long J.B. The kappa opioid agonist U-50,488 H antagonizes respiratory effects of mu opioid receptor agonists in conscious rats. J. Pharmacol. Exp. Ther. 264 (1993) 631-637
10. Emmanuelli J., and Desenclos J.C. Harm reduction interventions, behaviors and associated health outcomes in France, 1996-2003. Addiction 100 (2005) 1690-1700
11. Fone K.C., and Wilson H. The effects of alfentanil and selected narcotic analgesics on the rate of action potential discharge of medullary respiratory neurones in anaesthetized rats. Br. J. Pharmacol. 89 (1986) 67-79
12. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., Collins J., Raisch D., Casadonte P., Goldsmith R.J., Ling W., Malkerneker U., McNicholas L., Renner J., Stine S., and Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 349 (2003) 949-958
13. Gaulier J.M., Marquet P., Lacassie E., Dupuy J.L., and Lachatre G. Fatal intoxication following self-administration of a massive dose of buprenorphine. J. Forensic Sci. 45 (2000) 226-228
14. Gopal S., Tzeng T.B., and Cowan A. Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Eur. J. Pharm. Sci. 15 (2002) 287-293
15. Gueye P.N., Borron S.W., Risède P., Monier C., Buneaux F., Debray M., and Baud F.J. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol. Sci. 62 (2001) 148-154
16. Gueye P.N., Borron S.W., Risède P., Monier C., Buneaux F., Debray M., and Baud F.J. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol. Sci. 65 (2002) 107-114
17. Howell L.L., Bergman J., and Morse W.H. Effects of levorphanol and several kappa-selective opioids in respiration and behavior in rhesus monkeys. J. Pharmacol. Exp. Ther. 245 (1998) 364-372
18. Huang P., Kehner G.B., Cowan A., and Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 297 (2001) 688-695
19. Ibrahim R.B., Wilson J.G., Thorsby M.E., and Edwards D.J. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sci. 66 (2000) 1293-1298
20. Iribarne C., Picart D., Dreano Y., Bail J.P., and Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 60 (1997) 1953-1964
21. Kakko J., Svanborg K.D., Kreek M.J., and Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361 (2003) 662-668
22. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 121 (2001) 65-69
23. Kintz P. A new series of 13 buprenorphine-related deaths. Clin. Biochem. 35 (2002) 513-516
24. Kobayashi K., Yamamoto T., Chiba K., Tani M., Shimada N., Ishizaki T., and Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. 26 (1998) 818-821
25. Li A.P., Kaminski D.L., and Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104 (1995) 1-8
26. Ling G.S., Spiegel K., Lockhart S.H., and Pasternak G.W. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J. Pharmacol. Exp. Ther. 232 (1985) 149-155
27. Mahnke A., Strotkamp D., Roos P.H., Hanstein W.G., Chabot G.G., and Nef P. Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch. Biochem. Biophys. 337 (1997) 62-68
28. Mégarbane B., Pirnay S., Borron S.W., Trout H., Monier C., Risède P., Boschi G., and Baud F.J. Cerebral and plasma kinetics of a high dose of midazolam and correlations with its respiratory effects in rats. Toxicol. Lett. 159 (2005) 22-31
29. Mégarbane B., Marie N., Pirnay S., Borron S.W., Gueye P.N., Risède P., Monier C., Noble F., and Baud F.J. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol. Appl. Pharmacol. 212 (2006) 256-267
30. Morin-Surun M.P., Boudinot E., Gacel G., Champagnat J., Roques B.P., and Denavit-Saubie M. Different effects of mu and delta opiate agonists on respiration. Eur. J. Pharmacol. 98 (1984) 235-240
31. Ohtani M., Kotaki H., Sawada Y., and Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 272 (1995) 505-510
32. Ohtani M., Kotaki H., Nishitateno K., Sawada Y., and Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J. Pharmacol. Exp. Ther. 281 (1997) 428-433
33. Pasternak G.W. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16 (1993) 1-18
34. Pontani R.B., Vadlamani N.L., and Misra A.L. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 15 (1985) 287-297
35. Reisine T., and Pasternak G. Opioid analgesics and antagonists. In: Goodman A. (Ed). The Pharmacological Basis of Therapeutics (1996), McGraw-Hill, New-York 521-555
36. Reynaud M., Tracqui A., Petit G., Potard D., and Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am. J. Psychiatry 155 (1998) 448-449
37. 35S]GTP-gamma-S-functional binding assay. Synapse 34 (1999) 83-94
38. Sadee W., Rosenbaum J.S., and Herz A. Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J. Pharmacol. Exp. Ther. 223 (1982) 157-162
39. Shook J.E., Watkins W.D., and Camporesi E.M. Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression. Am. Rev. Respir. Dis. 142 (1990) 895-909
40. Sporer K.A. Buprenorphine: a primer for emergency physicians. Ann. Emerg. Med. 43 (2004) 580-584
41. Takita K., Herlenius E., Lindahl S.G., and Yamamoto Y. Actions of opioids on respiratory activity via activation of brainstem mu-, delta- and kappa-receptors; an in vitro study. Brain Res. 778 (1997) 233-241
42. Tallarida R.J., and Murray R.B. Manual of Pharmacologic Calculations with Computer Programs (1984), Springer-Verlag, New-York
43. Toll L., Berzetei-Gurske I.P., Polgar W.E., Brandt S.R., Adapa I.D., Rodriguez L., Schwartz R.W., Haggart D., O'Brien A., White A., Kennedy J.M., Craymer K., Farrington L., and Auh J.S. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 178 (1998) 440-466
44. Tracqui A., Kintz P., and Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 22 (1998) 430-434
45. Trieu L., and Murray M. Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem. Xenobiotica 30 (2000) 131-140
46. van den Hoogen R.H., and Colpaert F.C. Respiratory effects of morphine in awake unrestrained rats. J. Pharmacol. Exp. Ther. 237 (1986) 252-259
47. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., and Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55 (1994) 569-580
48. Walter D., and Inturrisi C. Absorption, distribution, metabolism and excretion of buprenorphine in animals and humans. In: Cowan A., and Lewis W. (Eds). Buprenorphine: Combating Drug Abuse with a Unique Opioid (1995), Wiley-Liss, New York 113-135
49. White J.M., and Rodney J.I. Mechanisms of fatal opioid overdose. Addiction 94 (1999) 961-972
50. Zhang W., Ramamoorthy Y., Tyndale R.F., and Sellers E.M. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes P450 in vitro. Drug Metab. Dispos. 31 (2003) 768-772
51. 35S)GTPγ S binding to membranes: determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 282 (1997) 676-684
52. Zuber R., Anzenbacherova E., and Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J. Cell. Mol. Med. 6 (2002) 189-198